Universität zu Köln

Schulze, Arik Bernard, Schmidt, Lars Henning, Heitkoetter, Birthe, Huss, Sebastian, Mohr, Michael, Marra, Alessandro, Hillejan, Ludger, Goerlich, Dennis, Barth, Peter J., Rehkaemper, Jan and Evers, Georg (2020). Prognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I-III NSCLC. Thorac. Cancer, 11 (1). S. 120 - 130. HOBOKEN: WILEY. ISSN 1759-7714

Full text not available from this repository.

Abstract

Background Epithelial-to-mesenchymal transition (EMT) is a crucial step in lung cancer pathogenesis. Among others, cancer-associated fibroblasts (CAFs) are reported to regulate this process. Objectives To investigate the prognostic and clinical impact, we analyzed CD34+ and SMA+ CAFs in non-small cell lung cancer (NSCLC). Methods Retrospectively, immunohistochemistry was performed to study stromal protein expression of both CD34 and SMA in 304 NSCLC patients with pTNM stage I-III disease. All tissue samples were embedded on tissue microarrays (TMAs). Results Our analysis revealed an association for CD34+ CAFs with G1/2 tumors and adenocarcinoma histology. Moreover CD34+ CAFs were identified as an independent prognostic factor (both for progression free survival [PFS] and overall survival [OS] in stage I-III NSCLC). Besides, SMA+ expression correlated with higher pTNM-tumor stages and lymphatic spread (pN stage). In turn, SMA-negativity was associated with improved PFS, but no prognostic impact was found on OS. Of interest, neither CD34+ CAFs nor SMA+ CAFs were associated with the primary tumor size, localization and depth of infiltration (pT stage). Conclusions CD34 was identified as an independent prognostic marker in pTNM stage I-III NSCLC. Moreover, loss of CD34+ CAFs might influence the dedifferentiation of the NSCLC tumor from its cell origin. Finally, SMA+ CAFs are more prevalent in NSCLC tumors of higher stages and lymphonodal positive NSCLC.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Schulze, Arik Bernard UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmidt, Lars Henning UNSPECIFIED UNSPECIFIED UNSPECIFIED Heitkoetter, Birthe UNSPECIFIED UNSPECIFIED UNSPECIFIED Huss, Sebastian UNSPECIFIED UNSPECIFIED UNSPECIFIED Mohr, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Marra, Alessandro UNSPECIFIED UNSPECIFIED UNSPECIFIED Hillejan, Ludger UNSPECIFIED UNSPECIFIED UNSPECIFIED Goerlich, Dennis UNSPECIFIED UNSPECIFIED UNSPECIFIED Barth, Peter J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Rehkaemper, Jan UNSPECIFIED UNSPECIFIED UNSPECIFIED Evers, Georg UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-127206
DOI:	10.1111/1759-7714.13248
Journal or Publication Title:	Thorac. Cancer
Volume:	11
Number:	1
Page Range:	S. 120 - 130
Date:	2020
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1759-7714
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CELL LUNG-CANCER; FIBROCYTES; STROMA; PROLIFERATION; PEMBROLIZUMAB; CHEMOTHERAPY; EXPRESSION; DOCETAXEL; CARCINOMA; NIVOLUMAB Multiple languages Oncology; Respiratory System Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/12720